Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn if video game-facilitated group activity helps to improve the quality of life and social function in inpatients with chronic schizophrenia.
The main questions it aims to answer are:
Researchers will compare video game-facilitated group activity to regular occupational therapy to see if the intervention is beneficial to patients with chronic schizophrenia.
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional arm | Active Comparator |
| |
| Controlled arm | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Video game-facilitated group activity | Behavioral | The intervention is a 12-week group activity program for each participant in the intervention group, and the program consists of three 50-minute video game facilitated group activity sessions per week. Participants in the intervention group will engage in those group activity session which will be mediated by the game of Super Mario Party on Nintendo Switch. |
| Measure | Description | Time Frame |
|---|---|---|
| The changes of quality of life | The changes of quality of life will be assessed by the World Health Organization Quality of Life-BREF (WHOQOL-BREF). | The outcome will be assessed at baseline, week 12, and week 24. |
| The changes of social function. | The changes of social function will be evaluated by the Personal and Social Performance Scale (PSP). | The outcome will be assessed at baseline, week 12, and week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| The changes of cerebral blood flow. | The changes in cerebral blood be measured by Near-Infrared Spectroscopy (NIRS). | The outcome will be assessed at baseline and week 12. |
| The change of cognitive function. |
| Measure | Description | Time Frame |
|---|---|---|
| Demographic data | Demographic data including age, sex, marital status, educational year, body mass index, past medical and allergic history, and other information related with this study will be assessed by research assistants. | Demographic data will be assessed at baseline. |
| The change of daily antipsychotic dose equivalences. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yung-Jen Yang | Tsao-Tun Psychiatric Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tsao-Tun Psychiatric Center, Ministry of Health and Welfare | Nantou City | Taiwan | 54249 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
The Montreal Cognitive Assessment (MoCA) will be used to evaluate changes in cognitive function.
| The outcome will be assessed at baseline and week 12. |
| The change of psychiatric symptoms. | The Brief Psychiatric Rating Scale (BPRS) will be used to assess changes in positive and negative psychiatric symptoms. | The outcome will be assessed at baseline and week 12. |
| The change of physical fitness | Physical fitness assessments will be conducted to measure changes in participants' physical fitness levels, including cardiopulmonary endurance, the strength and flexibility of upper and lower limbs, as well as dynamic and static balance.
| The outcome will be assessed at baseline and week 12. |
The dosage of antipsychotic medications of the participants will be calculated according to their usage of antipsychotic medications that are equivalent to 100 mg/day of chlorpromazine. The daily antipsychotic dose equivalences will be calculated by the average of the daily dose equivalences in the weeks that are scheduled to be assessed. |
| This outcome will be assessed at the baseline, Week 12, and Week 24. |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D012917 | Social Adjustment |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D012919 | Social Behavior |
| D001519 | Behavior |
Not provided
Not provided